MX2016014355A - Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. - Google Patents

Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.

Info

Publication number
MX2016014355A
MX2016014355A MX2016014355A MX2016014355A MX2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A MX 2016014355 A MX2016014355 A MX 2016014355A
Authority
MX
Mexico
Prior art keywords
full length
positions
numbering according
antibodies
length antibody
Prior art date
Application number
MX2016014355A
Other languages
English (en)
Inventor
Kettenberger Hubert
Schlothauer Tilman
Foged Jensen Pernille
Koenig Maximiliane
Rand Kasper
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016014355A publication Critical patent/MX2016014355A/es

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D31/00—Other cooling or freezing apparatus
    • F25D31/002—Liquid coolers, e.g. beverage cooler
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2600/00—Control issues
    • F25D2600/04—Controlling heat transfer
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2700/00—Means for sensing or measuring; Sensors therefor
    • F25D2700/16—Sensors measuring the temperature of products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Combustion & Propulsion (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para seleccionar un anticuerpo de longitud completa que comprende las etapas de a) generar de un anticuerpo de longitud completa precursor una pluralidad de anticuerpos de longitud completa aleatorizando uno o más residuos de aminoácido seleccionados a partir de los residuos de aminoácido en las posiciones 1-23 en el dominio variable de cadena pesada (numeración de conformidad con Kabat), en las posiciones 55-83 en el dominio variable de cadena ligera (numeración de conformidad con Kabat), en las posiciones 145-174 en el primer dominio constante de cadena pesada (numeración de conformidad con el índice EU) y en las posiciones 180- 97 en el primer dominio constante de cadena pesada (numeración de conformidad con el índice EU), b) determinar la intensidad de unión de cada uno de los anticuerpos de longitud completa a partir de la pluralidad de anticuerpos al receptor Fc neonatal humano (FcRn), y c) seleccionar un anticuerpo de longitud completa a partir de la pluralidad de anticuerpos de longitud completa que tiene una diferente intensidad de unión al FcRn que el anticuerpo de longitud completa precursor.
MX2016014355A 2014-06-12 2015-06-10 Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. MX2016014355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172180 2014-06-12
PCT/EP2015/062899 WO2015189249A1 (en) 2014-06-12 2015-06-10 Method for selecting antibodies with modified fcrn interaction

Publications (1)

Publication Number Publication Date
MX2016014355A true MX2016014355A (es) 2017-01-27

Family

ID=50933041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014355A MX2016014355A (es) 2014-06-12 2015-06-10 Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.

Country Status (10)

Country Link
US (2) US20170211876A1 (es)
EP (1) EP3155013B1 (es)
JP (2) JP6675329B2 (es)
KR (1) KR20170015920A (es)
CN (1) CN106459191B (es)
BR (1) BR112016025393A2 (es)
CA (1) CA2946430A1 (es)
MX (1) MX2016014355A (es)
RU (1) RU2714153C2 (es)
WO (1) WO2015189249A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001989A2 (pt) 2016-08-02 2019-08-20 Visterra Inc polipeptídeos projetados e usos dos mesmos
WO2019077092A1 (en) * 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
JP2022512798A (ja) * 2018-10-25 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー 抗体ＦｃＲｎ結合の改変
WO2021075930A1 (en) * 2019-10-16 2021-04-22 Lg Chem, Ltd. Neonatal fc receptor binding affimers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR100973564B1 (ko) * 2003-05-02 2010-08-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
RU2412200C2 (ru) * 2004-11-12 2011-02-20 Ксенкор, Инк. Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
WO2009032782A2 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2318436A4 (en) * 2008-08-14 2012-12-19 Cephalon Australia Pty Ltd ANTIBODIES OF DIFFERENT DOMAINS
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
JP5953303B2 (ja) * 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
AU2012323287B2 (en) * 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US9585970B2 (en) * 2012-06-04 2017-03-07 Novartis Ag Site-specific labeling methods and molecules produced thereby
AU2016211280B2 (en) * 2015-01-30 2021-11-25 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
EP4295154A1 (en) * 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions

Also Published As

Publication number Publication date
JP2020114217A (ja) 2020-07-30
US20170211876A1 (en) 2017-07-27
BR112016025393A2 (pt) 2017-12-12
CN106459191B (zh) 2021-12-10
WO2015189249A1 (en) 2015-12-17
EP3155013A1 (en) 2017-04-19
RU2714153C2 (ru) 2020-02-12
EP3155013B1 (en) 2019-03-27
JP7050838B2 (ja) 2022-04-08
CN106459191A (zh) 2017-02-22
JP2017525335A (ja) 2017-09-07
RU2016150952A (ru) 2018-07-12
JP6675329B2 (ja) 2020-04-01
RU2016150952A3 (es) 2019-02-07
CA2946430A1 (en) 2015-12-17
US20210041163A1 (en) 2021-02-11
KR20170015920A (ko) 2017-02-10

Similar Documents

Publication Publication Date Title
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
JOP20200213A1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12017502354A1 (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
CR20160090A (es) DIACUERPOS MONOVALENTES BIESPECÍFICOS QUE PUEDEN UNIRSE A gpA33 Y CD3, Y SUS USOS
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CL2017000711A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos.
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2019005426A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
MY187967A (en) Lag-3-binding molecules and methods of use thereof
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
MX353278B (es) Raton con cadena ligera comun.
PH12016501366A1 (en) Novel anti-baff antibodies
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
MX2016014355A (es) Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MY188871A (en) Pd-1-binding molecules and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration